How attacking a virus in cancer patients helped a Peninsula company target MS
As a Peninsula drug developer outlines its path for immunotherapy and next-generation cancer drugs, it also may have pointed the way toward a seemingly unrelated disease: multiple sclerosis.
Atara Biotherapeutics Inc. leaders believe the company's experimental tabelecleucel — or "tab-cel" — could halt Epstein-Barr virus. That common herpes virus threatens blood cancer patients after their immune systems are suppressed following a transplant from a bone marrow donor, and Atara's dr ug is designed…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Herpes | Immunotherapy | Multiple Sclerosis | Transplants